Our vision is to be a world-class commercial biotechnology company. We believe that we can achieve this with an approach of focused excellence in everything that we do-in working efficiently, in making data-driven decisions quickly, and in advancing promising compounds rapidly. Already, we have built one of the most impressive oncology development pipelines in the biotechnology and pharmaceutical industries.
More >>

EXEL (Common Stock) Exchange NASDAQ (US Dollar) Price $5.62 Change (%)   0.22 (4.07%) Volume 2,733,409 Data as of 01/27/12 3:59 p.m. ET Minimum 20 minute delay Refresh quote

Date Title   01/20/12 Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma 12/21/11 Exelixis Licenses PI3K-Delta Program to Merck 12/14/11 Exelixis Announces January 11 Webcast of Presentation at the J.P. Morgan 30th Annual Healthcare Conference 12/07/11 Exelixis' Cabozantinib Shows Encouraging Clinical Activity in Patients With Metastatic Breast Cancer

2010 Annual Report (pdf) 2009 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.